Oncocyte Corporation is a biotechnology company focused on developing innovative diagnostic solutions for cancer patients
The company specializes in the discovery and commercialization of proprietary tests that aid in the diagnosis, prognosis, and treatment selection for various types of cancer. By employing advanced genomics and other cutting-edge technologies, Oncocyte aims to provide healthcare professionals with valuable insights to improve patient outcomes and streamline the decision-making process in oncology. Through its research and development efforts, the company seeks to enhance precision medicine and support personalized treatment strategies in the fight against cancer.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQRARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Shares of Medical Properties Trust, Inc. (NYSEMPW) rose sharply in today’s pre-market trading after the company announced that it sold its majority interest in Utah Hospitals.
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Shares of NextPlat Corp (NASDAQNXPL) rose sharply in today’s pre-market trading after the company reported consolidated 2023 revenues of $37.8 million, up 222% year over year
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQIDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
The Dow Jones closed slightly higher on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
